SCHEMBL7082785

SCHEMBL7082785

CCOC(=O)c1nncn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.42
ALOX12 P18054 1/20 0.42
TSHR P16473 1/20 0.41
ALDH1A1 P00352 5/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
GAA P10253 3/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
PDE4D Q08499 1/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1564315 0.78 TSHR (0.41) TP53ALOX12TSHRALDH1A1MAPT
SCHEMBL27032230 0.77 SMN1; SMN2 (0.43) TP53ALDH1A1MAPTLMNAHPGD
SCHEMBL5365776 0.76 TP53 (0.45) TP53ALOX12TSHRALDH1A1MAPT
SCHEMBL7467650 0.76 TP53 (0.48) TP53ALOX12ALDH1A1MAPTLMNA
SCHEMBL1562665 0.74 TSHR (0.42) TP53ALOX12TSHRALDH1A1MAPT
SCHEMBL9571780 0.72 GABRG2 (0.42) TP53ALOX12ALDH1A1MAPTHPGD
SCHEMBL14487034 0.71 KDM4E (0.44) TP53ALOX12TSHRALDH1A1MAPT
SCHEMBL1562700 0.71 MAPT (0.45) TP53ALOX12TSHRALDH1A1MAPT
SCHEMBL11090937 0.71 GABRA2 (0.50) ALDH1A1MAPTLMNAGAAHPGD
SCHEMBL2893444 0.71 PDE4D (0.40) TP53ALOX12TSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 TP53 303/4885ALOX12 2363/4885TSHR 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.